Printed from Voxsanity (voxsanity.com.au) — NCT05899764 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Alzheimers Disease
Phase 2 Alzheimer's Disease Trial, Not Yet Recruiting
NCT05899764
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who meet recognised research criteria for mild cognitive impairment or Alzheimer's disease, with brain biomarkers that strongly suggest Alzheimer's-related changes.
- People aged 45 to 70 years old.
- People who show certain types of unusual electrical brain activity (epileptic activity and/or specific high-frequency signals) detected in particular areas of the brain.
- People who have a willing and available support person (such as a family member or carer) who has contact with them at least once a week.
- People who score 18 or above on a standard memory and thinking test (Mini-Mental State Examination) and/or score below 2 on a standard dementia rating scale (Clinical Dementia Rating) — these scores may come from a related UCLA study or be collected through a referring clinician.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have risk factors for unusual electrical brain activity (seizure-like activity) for reasons other than a brain-degenerating condition.
- People who are currently taking medications used to prevent or control seizures.
- People with severe damage to the white matter (the inner communication pathways) of the brain near the fluid-filled spaces.
- People with clinically significant small strokes deep in the brain (lacunar infarcts), as determined by a doctor.
- People who are currently taking blood-thinning (anticoagulant) medications.
- People with a serious illness affecting other parts of the body (confirm with trial site).
- People with a history of Korsakoff's syndrome (a brain disorder usually linked to severe alcohol use and vitamin deficiency).
- People with a history of alcohol or substance misuse that began before memory problems developed and continued within 5 years of when those problems started.
- People with an untreated vitamin B12 or folate (vitamin B9) deficiency.
- People with a history of head injury that caused lasting problems.
- People with untreated syphilis (a bacterial infection that can affect the brain).
- People with a history of multiple sclerosis or another condition involving inflammation of the nervous system.
- People with a history of dementia caused by problems with blood flow or multiple small strokes in the brain.
- People diagnosed with Huntington's disease.
- People with a history of normal pressure hydrocephalus (a condition where fluid builds up in the brain).
- People with a history of lesions (areas of damage or abnormal tissue) in the brain considered clinically significant by a doctor.
- People with an unresolved or current collection of blood between the brain and its outer covering (subdural hematoma).
- People with a history of bleeding inside the brain (intracerebral hemorrhage).
- People with serious liver disease.
- People whose kidneys function so poorly that they require dialysis.
- People who have had a brain infection such as encephalitis (brain inflammation) or meningitis (infection of the membranes around the brain).
- People with severe white matter disease in the brain, as measured by a score of 3 on a specific brain scan rating scale.
- People with small deep-brain strokes considered clinically significant by a doctor.
- People who have had a stroke affecting the outer layer of the brain (cortex).
- People with a breathing condition that requires ongoing oxygen use.
- People with untreated underactive thyroid (hypothyroidism).
- People with any other medical condition that the trial investigators consider likely to create an unacceptable risk of harm.
- People taking medications that are likely to affect how the brain works (such as benzodiazepines or narcotic pain medications) — note that people taking cholinesterase inhibitors or memantine may still be considered, provided the dose has been stable for at least 30 days before entering the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Keith A Vossel, MD, MSc, Mary S. Easton Center at UCLA
Phone: 310-206-8993
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 June 2029
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Brivaracetam on Cognition; Brivaracetam on Cognition
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.